Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.

TP53 mutations are associated with poor outcomes in acute myeloid leukemia (AML). The prognostic impact of mutant TP53 (TP53mut) variant allelic frequency (VAF) is not well established, nor is how this information might guide optimal frontline therapy. We retrospectively analyzed 202 patients with newly diagnosed TP53-mutated AML who underwent first-line therapy with either a cytarabine- or hypomethylating agent (HMA)-based regimen. By multivariate analysis, TP53mut VAF >40% was independently associated with a significantly higher cumulative incidence of relapse (P = .003) and worse relapse-free survival (P = .001) and overall survival (OS; P = .003). The impact of TP53mut VAF on clinical outcomes was driven by patients treated with a cytarabine-based regimen (median OS, 4.7 vs 7.3 months for VAF >40% vs ≤40%; P = .006), whereas VAF did not significantly affect OS in patients treated with HMA. The addition of venetoclax to HMA did not significantly affect OS compared with HMA without venetoclax, both in the entire TP53-mutated population and in patients stratified by TP53mut VAF. Among patients with TP53mut VAF ≤40%, OS was superior in those treated with higher-dose cytarabine, whereas OS was similarly poor for patients with TP53mut VAF >40% regardless of therapy. The best long-term outcomes were observed in those with 1 TP53 mutation with VAF ≤40% who received a frontline cytarabine-based regimen (2-year OS, 38% vs 6% for all others; P < .001). In summary, TP53mut VAF provides important prognostic information that may be considered when selecting frontline therapy for patients with newly diagnosed TP53-mutated AML.

[1]  M. Konopleva,et al.  Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. , 2020, Blood advances.

[2]  Qi Zhang,et al.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.

[3]  A. Berghold,et al.  Functional Classification of TP53 Mutations in Acute Myeloid Leukemia , 2019, Cancers.

[4]  H. Kantarjian,et al.  Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia , 2019, Cancer.

[5]  Jiqiang Yao,et al.  Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) , 2019, Blood.

[6]  P. Vyas,et al.  The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results , 2019, Blood.

[7]  M. Konopleva,et al.  Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia. , 2019, Journal of Clinical Oncology.

[8]  Eric R. Wolf,et al.  Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway , 2019, Nature Communications.

[9]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[10]  M. Konopleva,et al.  Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. , 2019, The Lancet. Haematology.

[11]  A. Berghold,et al.  Clinical implications of subclonal TP53 mutations in acute myeloid leukemia , 2018, Haematologica.

[12]  L. Bullinger,et al.  Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care , 2018, Leukemia.

[13]  J. Cortes,et al.  Acute myeloid leukaemia , 2018, The Lancet.

[14]  K. Patel,et al.  Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. , 2018, Blood.

[15]  M. Konopleva,et al.  Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia , 2018, American journal of hematology.

[16]  Molecular predictors of post-transplant survival in acute myeloid leukemia , 2017, Blood Cancer Journal.

[17]  M. Konopleva,et al.  Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. , 2017, Blood advances.

[18]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[19]  Thomas Efferth,et al.  The role of p53 in cancer drug resistance and targeted chemotherapy , 2016, Oncotarget.

[20]  Christopher A. Miller,et al.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.

[21]  Rashmi Kanagal-Shamanna,et al.  TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes , 2016, Cancer.

[22]  R. Bellazzi,et al.  Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Maciejewski,et al.  High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort , 2016, Leukemia.

[24]  N. Schmitz,et al.  Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  Christopher A. Miller,et al.  The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.

[26]  L. Bullinger,et al.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.

[27]  D. Neuberg,et al.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Kantarjian,et al.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.

[29]  J. Esteve,et al.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.

[30]  G. Juliusson,et al.  Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.

[32]  R. Hills,et al.  TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis , 2009, Leukemia.